Scientists test if powerful cancer drug can penetrate the Brain's defenses
NCT ID NCT06058988
Summary
This study aims to find out if the cancer drug trastuzumab deruxtecan (T-DXd) can get into brain tumors when given through an IV. Researchers will measure how much of the drug reaches the tumor during surgery in 30 adults with certain HER2-positive brain cancers or recurrent glioblastoma. The goal is to see if this drug could be an effective treatment option for these difficult-to-treat brain cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.